Canadian Media Releases 2002

Novartis Canada Media Releases 2002

11/15/02	Novartis Pharmaceuticals Canada Invests $15 Million in New National Head Office Building in Montreal

10/09/02	Health Canada Approves Drug that Addresses Unmet Need for Prostate Cancer Patients

09/24/02	Abrupt Discontinuation of Antispasmodic Drug Can Lead to Adverse Events Including Death

08/21/02	McGill University Health Centre Receives $1,000,000 From Novartis Pharmaceuticals

06/11/02	Novartis Pharmaceuticals Canada and Oryx Pharmaceuticals Introduce A New Treatment For Epilepsy

05/24/02	New Head-to-Head Data Show Gleevec® (imatinib mesylate) Achieves Nearly Three Times More Responses as First-Line Treatment for Chronic Myeloid Leukemia (CML) Patients than Interferon Combination Therapy

05/19/02	First Head-to-Head Worldwide Study of Leading Breast Cancer Drugs Shows…

01/15/02	World's Smallest Estrogen Replacement Therapy (ERT) Patch Available in Canada

DISCLAIMER FOR ARCHIVES
The information in our Media Release Archives was factually accurate on the date of publication. This information remains on our website for historical purposes only. Novartis Pharmaceuticals Canada Inc. assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon this information as current or accurate after their publication dates.